Boule Diagnostics AB (BOUL) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to our Q2 2026 earnings calls. My name is Michael Avinklefelt. I'm the CFO of Bull Diagnostics. And with me today, I have our new CEO, Johan Folkkunger, who joins us for his first investor call. We will be recording this session and after the formal presentation, we will open up for questions on the line and in the chat. With that, I hand it over to you, Johan. Thank you, Michael. So starting my new position on June 22nd, I have now been with the company for three weeks. I've spent this time familiarizing with the business and the organization to define priorities going forward. Despite the short time in the company, I'm impressed by the competence and commitment in the organization. There is a strong pride and engagement to continue the transformation to serve our markets and strengthen our business. In the near term, I will continue familiarising myself with the company and look forward to working together with the board of directors, management and employees to drive the transformation journey the company is going through. So let's look back at the second quarter, and I will conclude it has been a quarter characterised by a challenging market environment and geopolitical disruptions. And as we operate on a global market, this has clearly affected us. Sales so far in the year have decreased, much related to exchange rate fluctuations representing a significant headwind, but adding to that also a moderate underlying organic decline where the order intake for both instruments and consumables decreased compared to previous year. This is mainly due to the geopolitical tensions in the Middle East, including disruptions to shipping related to the situation in the Strait of Hormuz, but also related to limited access to US dollars for several key c...